CI Stock Movement Summary Cigna Group (CI) shares rose following several developments: Positive Factors: - Cigana reported Q4 2025 earnings that beat expectations - Revenue growth was lifted by its Evernorth pharmacy-benefit unit, which showed continued expansion - The company boosted its dividend on strong quarterly earnings - An FTC settlement was announced regarding Express Scripts' insulin pricing practices Negative Factors: - Cigana's 2026 earnings guidance of $30.25 per share fell below Wall Street analyst estimates - Projected 2026 revenue of approximately $280 billion also missed analyst forecasts - The company attributed lower guidance to its ongoing revamp of drug benefit plans - Sources cited continued medical cost and margin pressure The stock gained approximately 3% in trading Thursday, suggesting investors viewed the positive earnings results and FTC settlement as outweighing concerns about the below-consensus 2026 outlook.
Read full analysisCI Stock Movement Summary Cigna Group (CI) shares rose following several developments: Positive Factors: - Cigana reported Q4 2025 earnings that beat expectations - Revenue growth was lifted by its Evernorth pharmacy-benefit unit, which showed continued expansion - The company boosted its dividend on strong quarterly earnings - An FTC settlement was announced regarding Express Scripts' insulin pricing practices Negative Factors: - Cigana's 2026 earnings guidance of $30.25 per share fell below Wall Street analyst estimates - Projected 2026 revenue of approximately $280 billion also missed analyst forecasts - The company attributed lower guidance to its ongoing revamp of drug benefit plans - Sources cited continued medical cost and margin pressure The stock gained approximately 3% in trading Thursday, suggesting investors viewed the positive earnings results and FTC settlement as outweighing concerns about the below-consensus 2026 outlook.
The Cigna Group (CI) is a publicly traded company in the Healthcare sector.